Philip Mease1, Iain B McInnes2. 1. Swedish Medical Center and the University of Washington, Seattle, WA, USA. pmease@philipmease.com. 2. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Abstract
INTRODUCTION: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life. Biologic therapies that target tumor necrosis factor (anti-TNF) have significantly improved clinical outcomes. Partial, non- and transient responses remain common comprising significant unmet clinical need. New therapies with novel modes of action are urgently required. OBJECTIVES: The interleukin (IL)-17 pathway has recently been attributed a critical role in the pathogenesis of spondyloarthritides. Herein, we review data from clinical studies with secukinumab, a novel fully human IgG1κ anti-IL-17A monoclonal antibody (mAb), in patients with active PsA. RESULTS: Across two pivotal phase 3 studies, secukinumab provided significant and sustained reductions in the signs and symptoms of PsA, inhibition of radiographic progression, and improved patient-reported outcomes and measures of quality of life. The primary efficacy endpoint, a ≥20% improvement from baseline according to the American College of Rheumatology 20 (ACR20) response at Week 24, was significantly higher in patients treated with secukinumab compared with placebo, with improvements sustained through at least 52 weeks. Clinical benefits were seen with secukinumab regardless of concomitant methotrexate treatment and in patients who were either anti-TNF-naïve or who were inadequate responders to anti-TNF therapy. Secukinumab was well-tolerated, with a safety profile consistent with that previously reported in psoriasis trials. The most common adverse events were nasopharyngitis, upper respiratory tract infections, and headache. CONCLUSION: Secukinumab offers an effective new addition to the available treatment options for PsA. Regulatory submissions have been filed worldwide, with the first approvals recently obtained in Japan and Europe. Future studies are required to define the optimal timing and strategic use of this novel treatment modality. FUNDING: Novartis Pharma.
INTRODUCTION:Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life. Biologic therapies that target tumor necrosis factor (anti-TNF) have significantly improved clinical outcomes. Partial, non- and transient responses remain common comprising significant unmet clinical need. New therapies with novel modes of action are urgently required. OBJECTIVES: The interleukin (IL)-17 pathway has recently been attributed a critical role in the pathogenesis of spondyloarthritides. Herein, we review data from clinical studies with secukinumab, a novel fully human IgG1κ anti-IL-17A monoclonal antibody (mAb), in patients with active PsA. RESULTS: Across two pivotal phase 3 studies, secukinumab provided significant and sustained reductions in the signs and symptoms of PsA, inhibition of radiographic progression, and improved patient-reported outcomes and measures of quality of life. The primary efficacy endpoint, a ≥20% improvement from baseline according to the American College of Rheumatology 20 (ACR20) response at Week 24, was significantly higher in patients treated with secukinumab compared with placebo, with improvements sustained through at least 52 weeks. Clinical benefits were seen with secukinumab regardless of concomitant methotrexate treatment and in patients who were either anti-TNF-naïve or who were inadequate responders to anti-TNF therapy. Secukinumab was well-tolerated, with a safety profile consistent with that previously reported in psoriasis trials. The most common adverse events were nasopharyngitis, upper respiratory tract infections, and headache. CONCLUSION:Secukinumab offers an effective new addition to the available treatment options for PsA. Regulatory submissions have been filed worldwide, with the first approvals recently obtained in Japan and Europe. Future studies are required to define the optimal timing and strategic use of this novel treatment modality. FUNDING: Novartis Pharma.
Authors: Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245
Authors: Diamant Thaçi; Andrew Blauvelt; Kristian Reich; Tsen-Fang Tsai; Francisco Vanaclocha; Külli Kingo; Michael Ziv; Andreas Pinter; Sophie Hugot; Ruquan You; Marina Milutinovic Journal: J Am Acad Dermatol Date: 2015-06-17 Impact factor: 11.527
Authors: Mark G Lebwohl; Hervé Bachelez; Jonathan Barker; Giampiero Girolomoni; Arthur Kavanaugh; Richard G Langley; Carle F Paul; Lluís Puig; Kristian Reich; Peter C M van de Kerkhof Journal: J Am Acad Dermatol Date: 2014-02-24 Impact factor: 11.527
Authors: Jonathan P Sherlock; Barbara Joyce-Shaikh; Scott P Turner; Cheng-Chi Chao; Manjiri Sathe; Jeff Grein; Daniel M Gorman; Edward P Bowman; Terrill K McClanahan; Jennifer H Yearley; Gérard Eberl; Christopher D Buckley; Robert A Kastelein; Robert H Pierce; Drake M Laface; Daniel J Cua Journal: Nat Med Date: 2012-07-01 Impact factor: 53.440
Authors: Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett Journal: Ann Rheum Dis Date: 2014-03-04 Impact factor: 19.103
Authors: Rieke Alten; P G Conaghan; V Strand; E Sullivan; S Blackburn; H Tian; K Gandhi; S M Jugl; A Deodhar Journal: Clin Rheumatol Date: 2019-02-04 Impact factor: 2.980
Authors: Peter Nash; Iain B McInnes; Philip J Mease; Howard Thom; Matthias Hunger; Andreas Karabis; Kunal Gandhi; Shephard Mpofu; Steffen M Jugl Journal: Rheumatol Ther Date: 2018-03-31
Authors: Marco A Rocha Loures; Luciana C Macedo; Denise M Reis; Camila F Oliveira; Jean L Meneguetti; Gabriela F Martines; Janisleya S F Neves; Eliana de Souza; Ana M Sell; Jeane E L Visentainer Journal: Mediators Inflamm Date: 2018-04-19 Impact factor: 4.711
Authors: Peter Nash; Philip J Mease; Iain B McInnes; Proton Rahman; Christopher T Ritchlin; Ricardo Blanco; Eva Dokoupilova; Mats Andersson; Radhika Kajekar; Shephard Mpofu; Luminita Pricop Journal: Arthritis Res Ther Date: 2018-03-15 Impact factor: 5.156